MX2007006214A - Un implante para suministro de farmaco intraocular. - Google Patents

Un implante para suministro de farmaco intraocular.

Info

Publication number
MX2007006214A
MX2007006214A MX2007006214A MX2007006214A MX2007006214A MX 2007006214 A MX2007006214 A MX 2007006214A MX 2007006214 A MX2007006214 A MX 2007006214A MX 2007006214 A MX2007006214 A MX 2007006214A MX 2007006214 A MX2007006214 A MX 2007006214A
Authority
MX
Mexico
Prior art keywords
implant
end portion
opening
drug delivery
intraocular drug
Prior art date
Application number
MX2007006214A
Other languages
English (en)
Inventor
Andreas Reiff
Scott M Hampton
Richard Payne
Original Assignee
Therakine Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Therakine Ltd filed Critical Therakine Ltd
Publication of MX2007006214A publication Critical patent/MX2007006214A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61F—FILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
    • A61F2/00—Filters implantable into blood vessels; Prostheses, i.e. artificial substitutes or replacements for parts of the body; Appliances for connecting them with the body; Devices providing patency to, or preventing collapsing of, tubular structures of the body, e.g. stents
    • A61F2/02—Prostheses implantable into the body
    • A61F2/14—Eye parts, e.g. lenses, corneal implants; Implanting instruments specially adapted therefor; Artificial eyes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61F—FILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
    • A61F9/00—Methods or devices for treatment of the eyes; Devices for putting-in contact lenses; Devices to correct squinting; Apparatus to guide the blind; Protective devices for the eyes, carried on the body or in the hand
    • A61F9/0008—Introducing ophthalmic products into the ocular cavity or retaining products therein
    • A61F9/0017—Introducing ophthalmic products into the ocular cavity or retaining products therein implantable in, or in contact with, the eye, e.g. ocular inserts
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0048—Eye, e.g. artificial tears
    • A61K9/0051—Ocular inserts, ocular implants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/241—Tumor Necrosis Factors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61F—FILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
    • A61F2210/00—Particular material properties of prostheses classified in groups A61F2/00 - A61F2/26 or A61F2/82 or A61F9/00 or A61F11/00 or subgroups thereof
    • A61F2210/0004—Particular material properties of prostheses classified in groups A61F2/00 - A61F2/26 or A61F2/82 or A61F9/00 or A61F11/00 or subgroups thereof bioabsorbable
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61F—FILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
    • A61F2250/00—Special features of prostheses classified in groups A61F2/00 - A61F2/26 or A61F2/82 or A61F9/00 or A61F11/00 or subgroups thereof
    • A61F2250/0058—Additional features; Implant or prostheses properties not otherwise provided for
    • A61F2250/0067—Means for introducing or releasing pharmaceutical products into the body
    • A61F2250/0068—Means for introducing or releasing pharmaceutical products into the body the pharmaceutical product being in a reservoir

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Ophthalmology & Optometry (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Vascular Medicine (AREA)
  • Immunology (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Cardiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Oral & Maxillofacial Surgery (AREA)
  • Transplantation (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Materials For Medical Uses (AREA)
  • Media Introduction/Drainage Providing Device (AREA)
  • Infusion, Injection, And Reservoir Apparatuses (AREA)

Abstract

Un implante para suministro de farmaco intraocular para el tratamiento de enfermedades inflamatorias o degenerativas. En una modalidad, el implante incluye una porcion de cuerpo que tiene una primera porcion de extremo y una segunda porcion de extremo opuesta y que define una cavidad con una primera abertura en la primera porcion de extremo, y una segunda abertura opuesta en la segunda porcion de extremo, y un material solido recibido en la cavidad, en donde el material solido comprende un material de deposito y una cantidad efectiva de por lo menos un compuesto o agente terapeutico. Cuando el implante se implanta en un ojo de un sujeto vivo, la cantidad efectiva de por lo menos un compuesto o agente terapeutico se libera al medio ambiente del implante a traves de por lo menos una de la primera abertura y la segunda abertura opuesta durante un periodo prolongado de tiempo.
MX2007006214A 2004-11-24 2005-11-16 Un implante para suministro de farmaco intraocular. MX2007006214A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US63075104P 2004-11-24 2004-11-24
PCT/US2005/041330 WO2006057859A1 (en) 2004-11-24 2005-11-16 An implant for intraocular drug delivery

Publications (1)

Publication Number Publication Date
MX2007006214A true MX2007006214A (es) 2008-04-16

Family

ID=36498302

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2007006214A MX2007006214A (es) 2004-11-24 2005-11-16 Un implante para suministro de farmaco intraocular.

Country Status (12)

Country Link
US (2) US20060110429A1 (es)
EP (1) EP1827462A4 (es)
JP (1) JP2008521489A (es)
KR (1) KR20080016780A (es)
CN (1) CN101132800A (es)
AU (1) AU2005309854A1 (es)
BR (1) BRPI0518582A2 (es)
CA (1) CA2588449A1 (es)
IL (1) IL183424A0 (es)
MX (1) MX2007006214A (es)
RU (1) RU2007123604A (es)
WO (1) WO2006057859A1 (es)

Families Citing this family (69)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7431710B2 (en) 2002-04-08 2008-10-07 Glaukos Corporation Ocular implants with anchors and methods thereof
US7976520B2 (en) * 2004-01-12 2011-07-12 Nulens Ltd. Eye wall anchored fixtures
US20050232972A1 (en) 2004-04-15 2005-10-20 Steven Odrich Drug delivery via punctal plug
US7922702B2 (en) 2004-07-02 2011-04-12 Qlt Inc. Treatment medium delivery device and methods for delivery of such treatment mediums to the eye using such a delivery device
CN101132800A (zh) * 2004-11-24 2008-02-27 席拉坎有限责任公司 一种用于眼内药物释出的植入体
US20080199460A1 (en) * 2005-09-01 2008-08-21 Schering Corporation Use of IL-23 and IL-17 antagonists to treat autoimmune ocular inflammatory disease
AU2007293169A1 (en) * 2006-02-02 2008-03-13 Allergan, Inc. Compositions and methods for the treatment of ophthalmic disease
US8795711B2 (en) 2006-03-31 2014-08-05 Mati Therapeutics Inc. Drug delivery methods, structures, and compositions for nasolacrimal system
BRPI0621761A2 (pt) * 2006-06-12 2011-12-20 Therakine Ltd solução oftálmica e uso de uma solução salina, e uma quantidade eficaz de pelo menos um agente terapêutico
US9173773B2 (en) * 2006-06-21 2015-11-03 Johnson & Johnson Vision Care, Inc. Punctal plugs for the delivery of active agents
US9474645B2 (en) * 2006-06-21 2016-10-25 Johnson & Johnson Vision Care, Inc. Punctal plugs for the delivery of active agents
US20080045911A1 (en) * 2006-06-21 2008-02-21 Borgia Maureen J Punctal plugs for the delivery of active agents
AU2007272963B2 (en) 2006-07-11 2013-05-23 Refocus Group, Inc. Scleral prosthesis for treating presbyopia and other eye disorders and related devices and methods
US8911496B2 (en) 2006-07-11 2014-12-16 Refocus Group, Inc. Scleral prosthesis for treating presbyopia and other eye disorders and related devices and methods
WO2008045564A2 (en) * 2006-10-12 2008-04-17 Epix Delaware, Inc. Carboxamide compounds and their use as antagonists of the chemokine ccr2 receptor
WO2008073295A2 (en) * 2006-12-07 2008-06-19 Surmodics, Inc. Latent stabilization of bioactive agents releasable from implantable medical articles
AU2007339929A1 (en) * 2006-12-26 2008-07-10 Qlt Inc. Drug delivery implants for inhibition of optical defects
EP2205193A2 (en) 2007-09-07 2010-07-14 QLT Plug Delivery, Inc. Lacrimal implant detection
DK2207529T3 (en) 2007-09-07 2015-03-09 Mati Therapeutics Inc PHARMACEUTICAL cores for the sustained release of therapeutic agents
KR20100050566A (ko) 2007-09-07 2010-05-13 큐엘티 플러그 딜리버리, 인코포레이티드 눈물 임플랜트 및 이에 관련된 방법
RU2010128543A (ru) 2007-12-11 2012-01-20 Сайтопатфайндер, Инк. (Jp) Карбоксамидные соединения и их применение в качестве агонистов хемокиновых рецепторов
US20110053852A1 (en) * 2007-12-21 2011-03-03 Paul Klotman Use of podocan protein in treating cardiovascular diseases
CA3069576A1 (en) 2008-01-09 2009-07-16 The Schepens Eye Research Institute, Inc. Therapeutic compositions for treatment of ocular inflammatory disorders
JP2011509944A (ja) * 2008-01-14 2011-03-31 サーモディクス，インコーポレイティド 核酸送達複合体の溶出のための装置及び方法
CN104623741A (zh) 2008-04-30 2015-05-20 马缇医疗股份有限公司 复合泪管植入物及相关方法
WO2009137689A2 (en) * 2008-05-07 2009-11-12 Surmodics, Inc. Delivery of nucleic acid complexes from particles
JP2011520805A (ja) 2008-05-09 2011-07-21 キューエルティー プラグ デリバリー，インク． 緑内障および高眼圧症治療のための活性剤の持続送達
US10064819B2 (en) 2008-05-12 2018-09-04 University Of Utah Research Foundation Intraocular drug delivery device and associated methods
JP5591226B2 (ja) 2008-05-12 2014-09-17 ユニバーシティ・オブ・ユタ・リサーチ・ファウンデイション 眼内薬物送達装置および関連する方法
US9877973B2 (en) 2008-05-12 2018-01-30 University Of Utah Research Foundation Intraocular drug delivery device and associated methods
US9095404B2 (en) 2008-05-12 2015-08-04 University Of Utah Research Foundation Intraocular drug delivery device and associated methods
EP2315571A4 (en) * 2008-07-16 2013-05-01 Surmodics Pharmaceuticals Inc METHOD FOR PRODUCING MICROPARTICLES WITH BIOACTIVE PEPTIDES
CA2744245A1 (en) * 2008-11-19 2010-05-27 Refocus Group, Inc. Artificial intraocular lens, altered natural crystalline lens, or refilled natural crystalline lens capsule with one or more scleral prostheses for improved performance
US20120014970A1 (en) * 2009-01-09 2012-01-19 Reza Dana Therapeutic Compositions for Treatment of Corneal Disorders
EP2385839B1 (en) * 2009-01-09 2014-11-26 The Schepens Eye Research Institute, Inc. Therapeutic compositions for treatment of corneal disorders
WO2010093945A2 (en) 2009-02-13 2010-08-19 Glaukos Corporation Uveoscleral drug delivery implant and methods for implanting the same
MX2011008875A (es) 2009-02-23 2011-09-26 Quadra Logic Tech Inc Implantes lagrimales y metodos relacionados.
US10206813B2 (en) 2009-05-18 2019-02-19 Dose Medical Corporation Implants with controlled drug delivery features and methods of using same
JP5844258B2 (ja) * 2009-08-27 2016-01-13 バイオメット、バイオロジクス、リミテッド、ライアビリティー、カンパニーＢｉｏｍｅｔ Ｂｉｏｌｏｇｉｃｓ， Ｌｌｃ インターロイキン−１受容体アンタゴニストの生産のための植込み型装置
EP3470421B9 (en) 2010-07-29 2023-10-04 Buzzard Pharmaceuticals AB Chimeric il-1 receptor type i antagonists
US9668915B2 (en) 2010-11-24 2017-06-06 Dose Medical Corporation Drug eluting ocular implant
US8901092B2 (en) 2010-12-29 2014-12-02 Surmodics, Inc. Functionalized polysaccharides for active agent delivery
EP2711013A4 (en) * 2011-05-18 2015-03-04 Ajinomoto Kk IMMUNSTIMULANDS FOR ANIMALS, FEED THEREFOR AND MANUFACTURING PROCESS THEREFOR
US10245178B1 (en) 2011-06-07 2019-04-02 Glaukos Corporation Anterior chamber drug-eluting ocular implant
CN103889401B (zh) 2011-08-29 2017-10-13 Qlt公司 持续释放递送活性剂以治疗青光眼和高眼压
US9974685B2 (en) 2011-08-29 2018-05-22 Mati Therapeutics Drug delivery system and methods of treating open angle glaucoma and ocular hypertension
RU2642664C2 (ru) 2011-11-18 2018-01-25 Ридженерон Фармасьютикалз, Инк. Полимерные белковые микрочастицы
US9474715B2 (en) 2011-11-30 2016-10-25 Andreas Voigt Polymeric drug-delivery material, method for manufacturing thereof and method for delivery of a drug-delivery composition
KR101969594B1 (ko) * 2012-05-11 2019-04-16 서강대학교산학협력단 안내 약물 전달 임플란트
RS61391B1 (sr) * 2012-06-08 2021-02-26 Alkermes Pharma Ireland Ltd Ligandi modifikovani primenom cirkularnog permutiranja kao agonisti i antagonisti
RU2015143521A (ru) 2013-03-13 2017-04-19 Илэвэн Байотерапьютикс, Инк. Лекарственные формы химерных цитокинов для глазной доставки
US10517759B2 (en) 2013-03-15 2019-12-31 Glaukos Corporation Glaucoma stent and methods thereof for glaucoma treatment
CA2920653A1 (en) * 2013-08-08 2015-02-12 Loma Linda University Medical Center Systems and methods for the treatment of bladder cancer
TW201609145A (zh) * 2013-12-25 2016-03-16 參天製藥股份有限公司 注射劑及形成緩釋（ｄｅｐｏｔ）之方法
JP6655610B2 (ja) 2014-05-29 2020-02-26 グローコス コーポレーション 制御された薬物送達機能を備えるインプラント及びそれを使用する方法
FR3028410A1 (fr) 2014-11-18 2016-05-20 Pierre Coulon Implant capsulaire multifonctionnel
US11925578B2 (en) 2015-09-02 2024-03-12 Glaukos Corporation Drug delivery implants with bi-directional delivery capacity
WO2017037685A1 (en) * 2015-09-04 2017-03-09 University Of The Witwatersrand, Johannesburg Biodegradable implant
US11173130B2 (en) 2015-09-24 2021-11-16 Massachusetts Eye And Ear Infirmary Drug delivery system and methods of use
US11564833B2 (en) 2015-09-25 2023-01-31 Glaukos Corporation Punctal implants with controlled drug delivery features and methods of using same
EA036623B1 (ru) * 2015-10-16 2020-12-01 Ридженерон Фармасьютикалз, Инк. Стабильные белковые композиции
CN105497991B (zh) * 2016-01-07 2018-08-31 北京大学第三医院 聚羟基脂肪酸酯pha在制备治疗青光眼的产品中的应用
WO2017120479A1 (en) 2016-01-07 2017-07-13 The Schepens Eye Research Institute, Inc. Therapeutics for ocular immunoinflammatory diseases
US11318043B2 (en) 2016-04-20 2022-05-03 Dose Medical Corporation Bioresorbable ocular drug delivery device
WO2018175237A1 (en) * 2017-03-23 2018-09-27 Particle Sciences, Inc. Implantable and removable drug delivery device
IT201700101582A1 (it) * 2017-09-12 2019-03-12 Milano Politecnico Dispositivo per rilascio intraoculare
EP3843676A1 (en) * 2018-08-29 2021-07-07 W.L. Gore & Associates, Inc. Drug therapy delivery systems and methods
US11678983B2 (en) 2018-12-12 2023-06-20 W. L. Gore & Associates, Inc. Implantable component with socket
IT201900003597A1 (it) * 2019-03-12 2020-09-12 Milano Politecnico Dispositivo per il rilascio controllato

Family Cites Families (74)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3977404A (en) * 1975-09-08 1976-08-31 Alza Corporation Osmotic device having microporous reservoir
US5269812A (en) * 1986-05-16 1993-12-14 White Thomas C Methods and devices employed in replacement of the corneal endothelium
US5139518A (en) * 1986-05-16 1992-08-18 White Thomas C Methods employed in replacement of the corneal endothelium
US4863457A (en) * 1986-11-24 1989-09-05 Lee David A Drug delivery device
DK0454044T3 (da) * 1990-04-25 1996-04-22 Hoechst Ag Farmakologisk præparat indeholdende polyelektrolytkomplekser på mikropartikelform og mindst et virksomt stof
US5041081A (en) * 1990-05-18 1991-08-20 Odrich Ronald B Ocular implant for controlling glaucoma
US5830508A (en) * 1992-08-06 1998-11-03 Deo Corporation Composition for treating dry eye
US5707643A (en) * 1993-02-26 1998-01-13 Santen Pharmaceutical Co., Ltd. Biodegradable scleral plug
US5622965A (en) * 1993-03-12 1997-04-22 State Of Oregon, Acting By And Through The Oregon State Board Of Higher Education, Acting For And On Behalf Of The Oregon Health Sciences University And The University Of Oregon, Eugene Oregon 4-hydroxy-3-nitro-1,2-dihydroquinolin-2-ones and the use thereof as excitatory amino acid and glycine receptor antagonists
JPH08512056A (ja) * 1993-06-30 1996-12-17 ジェネンテク・インコーポレイテッド リポソームの製造法
US5466233A (en) * 1994-04-25 1995-11-14 Escalon Ophthalmics, Inc. Tack for intraocular drug delivery and method for inserting and removing same
US5885795A (en) * 1994-04-26 1999-03-23 The Children's Medical Center Corporation Methods of expressing angiostatic protein
US5837682A (en) * 1996-03-08 1998-11-17 The Children's Medical Center Corporation Angiostatin fragments and method of use
US5945403A (en) * 1997-05-30 1999-08-31 The Children's Medical Center Corporation Angiostatin fragments and method of use
US5639725A (en) * 1994-04-26 1997-06-17 Children's Hospital Medical Center Corp. Angiostatin protein
US6107045A (en) * 1994-06-30 2000-08-22 Oklahoma Medical Research Foundation Antibodies to lipoproteins and apolipoproteins and methods of use thereof
US6063396A (en) * 1994-10-26 2000-05-16 Houston Biotechnology Incorporated Methods and compositions for the modulation of cell proliferation and wound healing
US6063116A (en) * 1994-10-26 2000-05-16 Medarex, Inc. Modulation of cell proliferation and wound healing
US5900245A (en) * 1996-03-22 1999-05-04 Focal, Inc. Compliant tissue sealants
US5972326A (en) * 1995-04-18 1999-10-26 Galin; Miles A. Controlled release of pharmaceuticals in the anterior chamber of the eye
US5612027A (en) * 1995-04-18 1997-03-18 Galin; Miles A. Controlled release of miotic and mydriatic drugs in the anterior chamber
US5861372A (en) * 1996-02-22 1999-01-19 The Children's Medical Center Corporation Aggregate angiostatin and method of use
US5837240A (en) * 1995-04-28 1998-11-17 Oravax-Merieux Co. Multimeric, recombinant urease vaccine
US5968058A (en) * 1996-03-27 1999-10-19 Optonol Ltd. Device for and method of implanting an intraocular implant
EP0842209B1 (en) * 1995-07-28 2006-10-11 Genzyme Corporation Multiblock biodegradable hydrogels for use as controlled release agents for drugs and tissue treatment agents
US5773019A (en) * 1995-09-27 1998-06-30 The University Of Kentucky Research Foundation Implantable controlled release device to deliver drugs directly to an internal portion of the body
AR009439A1 (es) * 1996-12-23 2000-04-12 Novartis Ag Un articulo que comprende un sustrato con un recubrimiento polimerico primario que porta grupos reactivos predominantemente en su superficie, unmetodo para preparar dicho articulo, un articulo que posee un recubrimiento de tipo hibrido y una lente de contacto
DE69816980T2 (de) * 1997-03-31 2004-07-22 Alza Corp., Palo Alto Implantierbares diffusionabgabesystem
US6224893B1 (en) * 1997-04-11 2001-05-01 Massachusetts Institute Of Technology Semi-interpenetrating or interpenetrating polymer networks for drug delivery and tissue engineering
US6638621B2 (en) * 2000-08-16 2003-10-28 Lyotropic Therapeutics, Inc. Coated particles, methods of making and using
US6186148B1 (en) * 1998-02-04 2001-02-13 Kiyoshi Okada Prevention of posterior capsular opacification
CA2320515A1 (en) * 1998-02-13 1999-08-19 Human Genome Sciences, Inc. Therapeutic uses of keratinocyte growth factor-2
US7101575B2 (en) * 1998-03-19 2006-09-05 Max-Planck-Gesellschaft Zur Forderung Der Wissenschaften E.V. Production of nanocapsules and microcapsules by layer-wise polyelectrolyte self-assembly
WO1999047253A1 (en) * 1998-03-19 1999-09-23 MAX-PLANCK-Gesellschaft zur Förderung der Wissenschaften e.V. Fabrication of multilayer-coated particles and hollow shells via electrostatic self-assembly of nanocomposite multilayers on decomposable colloidal templates
US20020099438A1 (en) * 1998-04-15 2002-07-25 Furst Joseph G. Irradiated stent coating
EP1098696B2 (de) * 1998-07-15 2010-07-14 Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. Polyelektrolythüllen auf biologischen templaten
EP1098642B1 (en) * 1998-07-27 2007-04-04 Johns Hopkins University Diamino-propanol-compounds for treating ischemia
EP1107791B8 (en) * 1998-09-04 2007-11-07 Scios Inc. Hydrogel compositions for the controlled release administration of growth factors
US6630457B1 (en) * 1998-09-18 2003-10-07 Orthogene Llc Functionalized derivatives of hyaluronic acid, formation of hydrogels in situ using same, and methods for making and using same
IT1302534B1 (it) * 1998-12-21 2000-09-05 Fidia Advanced Biopolymers Srl Composizioni iniettabili, biocompatibili e biodegradabili comprendentialmeno un derivato dell'acido ialuronico, cellule condrogeniche, per
US6395029B1 (en) * 1999-01-19 2002-05-28 The Children's Hospital Of Philadelphia Sustained delivery of polyionic bioactive agents
US6217895B1 (en) * 1999-03-22 2001-04-17 Control Delivery Systems Method for treating and/or preventing retinal diseases with sustained release corticosteroids
FR2791552B1 (fr) * 1999-04-02 2001-10-19 Georges Baikoff Implant pour la correction de la presbytie des yeux phaques
US6312725B1 (en) * 1999-04-16 2001-11-06 Cohesion Technologies, Inc. Rapid gelling biocompatible polymer composition
JP4970678B2 (ja) * 1999-06-10 2012-07-11 マックス−プランク−ゲゼルシャフト・ツア・フェルデルング・デア・ヴィッセンシャフテン・エー・ファオ 多層コーティングによる結晶のカプセル化
US6331313B1 (en) * 1999-10-22 2001-12-18 Oculex Pharmaceticals, Inc. Controlled-release biocompatible ocular drug delivery implant devices and methods
US6204270B1 (en) * 1999-11-12 2001-03-20 Eyal S. Ron Ophthalmic and mucosal preparations
DE60041978D1 (de) * 1999-11-15 2009-05-20 Biocure Inc Auf äussere bedingungen ansprechende polymere hohle partikel
US6267954B1 (en) * 1999-11-24 2001-07-31 Universite De Paris V Rene-Descartes Intraocular transplantation of encapsulated cells
DE10001172A1 (de) * 2000-01-13 2001-07-26 Max Planck Gesellschaft Templatieren von Feststoffpartikeln mit Polymermultischichten
US20030186386A1 (en) * 2000-02-11 2003-10-02 Hansen Christian Karsten Interleukin 10
US6375972B1 (en) * 2000-04-26 2002-04-23 Control Delivery Systems, Inc. Sustained release drug delivery devices, methods of use, and methods of manufacturing thereof
EP1286634B1 (en) * 2000-05-19 2007-11-07 Michael S. Berlin Laser delivery system and method of use for the eye
US20040170665A1 (en) * 2000-06-02 2004-09-02 Allergan, Inc. Intravitreal botulinum toxin implant
US6458275B1 (en) * 2000-06-05 2002-10-01 Harvard Apparatus, Inc. Multi-well equilibrium dialysis system
ES2312456T3 (es) * 2000-08-30 2009-03-01 Johns Hopkins University Dispositivos para suministro intraocular de farmacos.
AU2002248284A1 (en) * 2000-11-01 2002-08-06 Allergan, Inc. Compositions for treatment of ocular neovascularization
WO2002053130A2 (en) * 2001-01-03 2002-07-11 Bausch & Lomb Incorporated Sustained release drug delivery devices with coated drug cores
US6713081B2 (en) * 2001-03-15 2004-03-30 The United States Of America As Represented By The Department Of Health And Human Services Ocular therapeutic agent delivery devices and methods for making and using such devices
US6849271B2 (en) * 2001-04-27 2005-02-01 Verion, Inc. Microcapsule matrix microspheres, absorption-enhancing pharmaceutical compositions and methods
US20030211464A1 (en) * 2001-05-02 2003-11-13 Charles Pidgeon Method and compositions for drug discovery
JP4531290B2 (ja) * 2001-05-18 2010-08-25 大日本印刷株式会社 保護拡散フィルム、面光源装置及び液晶表示装置
US20040062768A1 (en) * 2001-06-05 2004-04-01 Advanced Biotherapy, Inc. Compositions and methods for treating hyperimmune response in the eye
EP2316394B1 (en) * 2001-06-12 2016-11-23 The Johns Hopkins University Reservoir device for intraocular drug delivery
CA2456806C (en) * 2001-08-08 2011-10-18 Brown University Research Foundation Methods for micronization of hydrophobic drugs
WO2003039404A2 (en) * 2001-11-09 2003-05-15 Eyetech Pharmaceuticals Methods for treating ocular neovascular diseases
CA2473355C (en) * 2002-01-18 2012-01-03 Michael E. Snyder Sustained release ophthalmological device and method of making and using the same
CN1732022A (zh) * 2002-12-30 2006-02-08 血管技术国际股份公司 含有丝的支架移植物
AR043356A1 (es) * 2003-01-24 2005-07-27 Control Delivery Sys Inc Dispositvo de liberacion sostenida para la administracion ocular de inhibidores de la anhidrasa carbonica y uso de inhibidores de la anhidrasa carbonica para su preparacion
US7241455B2 (en) * 2003-04-08 2007-07-10 Boston Scientific Scimed, Inc. Implantable or insertable medical devices containing radiation-crosslinked polymer for controlled delivery of a therapeutic agent
US7332470B2 (en) * 2003-04-15 2008-02-19 The Regents Of The University Of California Methods and compositions for treating ocular disease
US6923996B2 (en) * 2003-05-06 2005-08-02 Scimed Life Systems, Inc. Processes for producing polymer coatings for release of therapeutic agent
US7364585B2 (en) * 2003-08-11 2008-04-29 Boston Scientific Scimed, Inc. Medical devices comprising drug-loaded capsules for localized drug delivery
CN101132800A (zh) * 2004-11-24 2008-02-27 席拉坎有限责任公司 一种用于眼内药物释出的植入体

Also Published As

Publication number Publication date
US20090214619A1 (en) 2009-08-27
JP2008521489A (ja) 2008-06-26
KR20080016780A (ko) 2008-02-22
AU2005309854A1 (en) 2006-06-01
US20060110429A1 (en) 2006-05-25
RU2007123604A (ru) 2008-12-27
WO2006057859A1 (en) 2006-06-01
CA2588449A1 (en) 2006-06-01
EP1827462A1 (en) 2007-09-05
CN101132800A (zh) 2008-02-27
BRPI0518582A2 (pt) 2008-11-25
IL183424A0 (en) 2008-04-13
EP1827462A4 (en) 2012-01-04

Similar Documents

Publication Publication Date Title
MX2007006214A (es) Un implante para suministro de farmaco intraocular.
WO2004010975A3 (en) Controlled drug delivery
NZ583861A (en) Lacrimal implants with an angled intersection between its sections so as to bias a portion of the body against the tissue surface
WO2009102787A3 (en) Medical implants with polysaccharide drug eluting coatings
MX2007002688A (es) Dispositivo para administrar agentes bioactivos y metodo de fabricacion.
WO2007076508A3 (en) Implantable graft material
WO2008108987A3 (en) Medical device with a porous surface for delivery of a therapeutic agent
MX2009005405A (es) Sistemas intraoculares de distribucion de farmaco.
WO2006079055A3 (en) Apparatus and method for delivering therapeutic and/or other agents to the inner ear and to other tissues
WO2006033779A3 (en) Energetically controlled delivery of biologically active material from an implanted medical device
WO2008027371A3 (en) Low profile bioactive agent delivery device
IL194515A (en) Implants for epic-tear drainage system for drug therapy
WO2006113866A3 (en) Internal joint for medical devices
ATE415907T1 (de) Festes implantat
WO2001008717A9 (en) Controlled release implantable devices
WO2007133520A3 (en) Stent coating comprising titanium oxide or iridium oxide and a therapeutic agent
WO2006023803A3 (en) Methods of administering microparticles combined with autologous body components
NZ583832A (en) Implant insertion tool with a tissue stop configuired to engage tissue
WO2008002586A3 (en) Coatings for medical devices comprising a therapeutic agent and a metallic material
WO2006041942A3 (en) Ocular delivery of polymeric delivery formulations
WO2010039641A3 (en) Long term drug delivery devices with polyurethane-based polymers and their manufacture
ATE416798T1 (de) Medizinprodukt mit gewebeabhängiger arzneimittelelution
CA2235919A1 (en) Non-polymeric sustained release delivery system
WO2007070790A3 (en) Self-sensing stents, smart materials-based stents, drug delivery systems, other medical devices, and medical uses for piezo-electric materials
IL171115A (en) An implantable polymeric device for the sustained release of a dopamine agonist

Legal Events

Date Code Title Description
GB Transfer or rights
FG Grant or registration
HH Correction or change in general